secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001628280-23-017984
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical Q1 revenue $19.7M (+22.4% YoY); net loss narrows to $0.10/share
--------------------------------------------------------------------------------

- Revenue of $19.7M, up 22.4% YoY; gross profit of $2.6M vs gross loss of $0.8M in Q1 2022.
- Net loss of $1.75M ($0.10/share) vs $7.2M ($0.84) a year ago; operating loss improved to $1.4M.
- Reiterates 2023 guidance: revenue $78-82M, gross profit $7-9M, targeting profitability in 2024.
- Signed long-term supply agreements with largest U.S. non-profit dialysis provider and Concerto Renal Services.
- Assumed full commercial responsibility for Baxter customers; cash stood at $16.8M at quarter-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828023017984/0001628280-23-017984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828023017984/rmti-20230515.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-017984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer